Capricorn Therapeutics shares rose 65% after the US Food and Drug Administration agreed to review the latest data on its new Duchenne muscular dystrophy drug.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.